Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells

Cancer Research

Volumn 63, Issue 14, 2003, Pages 4044-4047

  Shingu, Takashi ^a   Yamada, Kazuo ^a   Hara, Nobumasa ^a   Moritake, Kouzo ^a   Osago, Harumi ^a   Terashima, Masaharu ^a   Uemura, Takeshi ^a   Yamasaki, Toshiki ^a   Tsuchiya, Mikako ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALKYLATING AGENT; CARMUSTINE; CASPASE 3; CISPLATIN; ETOPOSIDE; GYRASE INHIBITOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CHROMONES; CISPLATIN; DRUG SYNERGISM; ENZYME INHIBITORS; ETOPOSIDE; GLIOMA; HUMANS; MICROTUBULES; MORPHOLINES; PACLITAXEL; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0041672472     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Johnstone, R. W., Ruefli, A. A., and Smyth, M. J. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem. Sci., 25: 1-6, 2000.
2. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenesis and therapeutic agents. Cancer Res., 50: 6119-6129, 1990.
3. Johnstone, R. W., Ruefli, A. A., and Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108: 153-164, 2002.
4. DeAngelis, L. M. Brain tumors. N. Engl. J. Med., 344: 114-123, 2001.
5. Weller, M., Rieger, J., Grimmel, C., Van Meir, E. G., De Tribolet, N., Krajewski, S., Reed, J. C., von Deimling, A., and Dichgans, J. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses, Int. J. Cancer, 79: 640-644, 1998.
6. Smith, J. S., Tachibana, I., Passe, S. M., Huntly, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., Buckner, J. C., and Jenkins, R. B. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer Inst. (Bethesda), 93: 1246-1256, 2001.
7. Shingu, T., Yamada, K., Hara, N., Moritake, K., Osago, H., Terashima, M., Uemura, T., Yamasaki, T., and Tsuchiya, M. Growth inhibition of human malignant glioma cells by the PI3K-specific inhibitor. J. Neurosurg., 98: 154-161, 2003.
8. Steel, G. G., and Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys., 5: 85-91, 1979.
9. Kano, Y., Suzuki, K., Akutsu, M., Suda, K., Inoue, Y., Yoshida, M., Sakamoto, S., and Miura. Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer, 50: 604-610, 1992.
10. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effective relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
11. Kaufmann, S. H., Peereboom, D., Buckwalter, C. A., Svingen, P. A., Grochow, L. B., Donehower, R. C., and Rowinsky, E. K. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J. Natl. Cancer Inst. (Bethesda), 88: 734-741, 1996.
12. Roymans, D., and Slegers, H. Phosphatidylinositol 3-kinases in tumor progression. Eur. J. Biochem. 268: 487-498, 2001.
13. Hu, L., Hofmann, J., Lu, Y., Mills, G. B., and Jaffe, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res., 62: 1087-1092, 2002.
14. Mason, W., Louis, D. N., and Caimcross, J. G. Chemosensitive gliomas in adults: which ones and why? J. Clin. Oncol., 15: 3423-3426, 1997.
15. Jackson, D. V. J., Sethi, V. S., Spurr, C. L., and McWhorter, J. M. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res., 41: 1466-1468, 1981.
16. Glantz, M. J., Choy, H., Kearns, C. M., Mills, P. C., Wahlberg, L. U., Zuhowski, E. G., Calabresi, P., and Egorin, M. J. Paclitaxel disposition in plasma and central nervous system of humans and rats with brain tumors. J. Natl. Cancer Inst. (Bethesda), 87: 1077-1081, 1995.
17. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem., 269: 5241-5248, 1994.
18. Limbourg, F. P., Huang, Z., Plumier, J. C., Simoncini, T., Fujioka, M., Tuckermann, J., Schutz, G., Moskowitz, M. A., and Liao, J. K. Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J. Clin. Investig., 110: 1729-1738, 2002.
19. Fellner, S., Bauer, Bjorn., Miller, D. S., Schaffrik, M., Fankhanel, M., Sprub, T., Bernhardt, G., Graeff, C., Farber, L., Gschaidmeier, H., Buschauer, A., and Fricker, G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Investig., 110: 1309-1318, 2002.